These results indicated that the inhibition of expression and activity of HK2 by GP‐2250 decreases cell glycolysis and increases ROS level (Figure S3); as a result, GP‐2250 increases anti‐neoplastic effects on cancer cells. Here, HK2 is linked to cancer.